Very few of the "hard" 3-point MACE (cardio death, non-fatal MI, non-fatal stroke) occurred in those trials. 3-point MACE is the primary outcome of BETonMACE.

You state there were VERY FEW 3-point MACE events that occurred n the Phase 2,..

I would have thought the company would have done a trial using the 5-point MACE instead of the 3-point MACE just to be more sure of the outcome. That's a big, long, and expensive trial to do based on something that you did not test before in a smaller phase.

Why do you think they chose to take that risk,..?

Is there no market for the great 5-point MACE results,..or are there other drugs already out there that do the job with 5-point MACE,...?

Is there any chance they might have seen something positive that convinced them that the results for 3-point MACE would be just about as good,...?